Oncolytics Biotech
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 26
- Market Cap
- $74.3M
- Introduction
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Ma...
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
- Conditions
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 14
- Registration Number
- NCT00753038
- Locations
- 🇺🇸
Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
- Conditions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 18
- Registration Number
- NCT00528684
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸The Ohio State University Medical Center and Arthur G. James Cancer Hospital and Richard J. Solove Research Center, Columbus, Ohio, United States
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 53
- Registration Number
- NCT00503295
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Institute of Drug Development, Cancer Therapy Research Center, San Antonio, Texas, United States
🇺🇸University of Michigan Medical School, Ann Arbor, Michigan, United States